Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
Conditions: Hepatocellular Carcinoma; Adjuvant Immunotherapy; Checkpoint Inhibitor Interventions: Drug: Anti-PD-1 monoclonal antibody Sponsors: Chen Xiaoping Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Immunotherapy | Liver Cancer | Research